Daily Program

/Daily Program
Daily Program2018-05-14T13:37:48+00:00

MIXiii-Biomed 2018 Scientific Program                                                                                                                  

Time slots in blue text indicate Company Presentations
To view an abstract, click on the highlighted company name

Tuesday, May 15, 2018

07:30  -  17:00

Registration Open

09:30  -  11:20
Hall A

Opening Session

09:30-09:50 Welcome by Conference Chairperons:
Ruti Alon, Founder and CEO, Medstrada
Ora Dar, PhD, Israel Innovation Authority
Nissim Darvish, MD, PhD, Senior Managing Director, OrbiMed

09:50-10:35 Arie S. Belldegrun MD, FACS, Founder, Kite Pharma; Executive Chairman & Co-Founder, Allogene Therapeutics: “Passing the Torch”

10:35-11:20 Francois Maisonrouge, Senior Managing Director, Evercore Partners:  “Health Care in 2020: Will we still Pay for Innovation?”

11:20  -  11:50

Coffee Break

11:50  -  17:45
Hall A

Next Generation Oncology Treatments

Chair: Prof. David Sidransky, MD, Johns Hopkins School of Medicine and Israel Biotech Fund, Co-Founder and General Partner

Immune Oncology
11:50-11:55 Prof. David Sidransky, MD, Johns Hopkins School of Medicine and Israel Biotech Fund, Co-Founder and General Partner

11:55-12:35 Prof. Jeffrey A. Sosman, MD, Director, Melanoma Program, Director, Faculty Development, Co-Leader, Translational Research in Solid Tumors, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

12:35-12:50 Julian Adams, Chairman & CEO, Gamida Cell

12:50-13:05 Yaron Pereg, CEO, Kahr Medical: “KAHR Medical Dual Signaling Proteins (DSP) Platform – the Next Generation of Cancer Immunotherapy”

13:05-13:20 Tehila Ben Moshe, CEO,Biond Biologics: “Biond Biologics- Translating Great Science to Innovative Bio Therapies”

13:20-13:35 Aviv Boim, CEO, Tikcro Technologies: “Immune Oncology – Selective Blocking Antibodies”

13:35-13:50 Irit Carmi-Levy, Drug Development Manager, BiolineRX: “AGI-134: Small Molecule Inducing Hyper-acute, Multi-arm Immune Response Targeting Tumor-specific Neoantigens”

13:50-15:20 Lunch Break

15:20-15:40 Phil L’Huillier, PhD, MBA,  Head, European Innovation Hub, MSD: “MSD Immuno-Oncology Overview”

15:40-16:00 Tal Zaks, MD, PhD, Chief Medical Officer Moderna Therapeutics: “Translating mRNA Vaccines and Therapeutics into IO Agents”

16:00-16:15 Dror Harats, MD, CEO Vascular Therapeutics: “MOSPD2: A Novel Target for Antibody-Mediated Killing of Tumor Cells”

16:15-16:30 Roni Mamluk, PhD, CEO, Ayala Pharmaceuticals: “Ayala – A New Clinical Stage Precision Oncology Company”

16:30-16:45 Ori Kalid, Co-Founder & CEO, Pi Therapeutics: “Novel First-in-class Inhibitors of Protein Degradation – an Unfolding Story”

16:45-17:00 Gil Hakim, President, IL Operations, UroGen Pharma: “Transforming Local Therapies in Urology”

17:00-17:45 Roundtable Discussion: Precision Medicine in Oncology
Prof. Jeffrey A. Sosman, MD, Director, Melanoma program, Director, Faculty Development, Co-Leader, Translational Research in Solid Tumors, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Phil L’Huillier, PhD, MBA,  Head, European Innovation Hub, MSD
Tal Zaks, MD, PhD, Chief Medical Officer Moderna Therapeutics
Roni Mamluk, PhD, CEO, Ayala Pharmaceuticals
Dror Harats, MD, CEO Vascular Therapeutic

11:50  -  17:15
Hall B

Fighting Rare Genetic Diseases Using Novel Therapeutic Approaches

Chair: Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx

11:50-12:00 Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx: “Opening Remarks”

12:00-12:15 Julia Hawkins, Partner, LocalGlobe: “The Journey of a Parent to a Child with a Rare Genetic Condition”

12:15-12:35 Tal Zaks, MD, PhD, Chief Medical Officer Moderna Therapeutics: “Moderna mRNA Therapies for Rare Genetic Diseases”

12:35-12:50 BatSheva Kerem, Founder, SpliSense: “Antisense Oligonucleotide Based Treatment for Cystic Fibrosis”

12:50-13:05 Robert Ward, CEO, Eloxx Pharmaceuticals: “About Eloxx Pharmaceuticals”

13:05-13:20 Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx: “From Small Molecules to Gene Therapy and Everything in Between”

13:20-13:35 Prof. Nissim Benvenisty, MD, PhD, New Stem Ltd: Human Haploid Pluripotent Stem Cells”

13:35-13:50  Aleks ScheinART BioScience: “mRNA Therapeutics for the Treatment of Rare Diseases”

13:50-15:20 Lunch Break

15:20-15:35 Natalie Yivgi Ohana, PhD, Founder & Chief Scientist, Minovia Therapeutics: “Mitochondria Augmentation Therapy for Rare Mitochondrial Diseases”

15:35-15:50 Or Kakhlon, Department of Neurology, Hadassah Medical Organization: “Using Small Molecules to Treat Glycogen Storage Disorders: New Mechanistic and Translational Insights”

15:50-16:05 Chris Adams, PhD, MBA, Chief Executive Officer, Cydan II Inc: “Rare Disease Company Formation”

16:05-16:20 Daniel Fischer, Founder at Tevard Biosciences: “A Parent on the Race to Find a Therapy for Dravet Syndrome”

16:20-16:35 Tauhid Ali, PhD, Vice President and Head of TAK-celerator, Takeda: “A Rare Disease Unit within Big Pharma”

16:35-17:15 Panel: Rare Diseases – Not a Rare Success. Developing Therapies for Rare Genetic Diseases
Moderator: Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx
Julia Hawkins, Partner, LocalGlobe
Tauhid Ali, PhD, Vice President and Head of TAK-celerator, Takeda
Chris Adams, PhD, MBA, Chief Executive Officer, Cydan II Inc.
Daniel Fischer, Founder at Tevard Biosciences

11:50  -  17:45
Hall C

Novel Clinical Trial Designs and Technologies to Accelerate Drug Development

Chair: Iris Grossman, PhD, Chief Scientific Officer, Camp4 Therapeutics

11:50-12:00 Iris Grossman, PhD, Chief Scientific Officer, Camp4 Therapeutics: “Introduction”

12:00-12:20 Iris Grossman, PhD, Chief Scientific Officer, Camp4 Therapeutics: “Regulatory Landscape, from Cures Act to INFORMED, Recent Guidances and Future Perspective”

12:20-12:35 Erhan Bilal, PhD, IBM Research, Computational Biology Center: “Sensor-based Assessment of Parkinson’s Disease”

12:35-12:50 Marc Funk, COO & President, Lonza Pharma & Biotech: “Novel Tools to Accelerate Early Drug R&D”

12:50-13:05 Daphna Laifenfeld, PhD, Chief Strategy Officer, Ibex Medical Analytics: “Data Driven Repurposing of Existing Drugs”

13:05-13:50 Panel Discussion
Panelists: All

13:50-15:20 Lunch Break

15:20-15:35 Dan Vesely, Co-founder, CliniCrowd, Partner at Sdemagroup: “Patient-driven R&D and the Power of Crowd Source for Therapeutics”

15:35-15:50 Avital Pushett, Business Development, NeuroSense: “Repurposed and Abbreviated ALS Disease Modifying Therapeutic Development”

15:50-16:05 Yoran Bar, Founder & CEO, BeaconCure: “Accelerating Clinical Submissions via Text Analytics AI”

16:05-16:20 Chen Admati, Head of Intel Pharma Analytics Platform, Intel Corporation “From Sensors to Therapeutics via Machine Leaning”

16:20-16:35 Nadav Kidron, CEO, OraMed Pharmaceuticals: “Abbreviated Drug Development: Patient-centered Approaches to Innovation”

16:35-16:50 Natalie Gavrielov, PhD, Scientific Lead, Data2Life: “Patient Voice in R&D – Proactive Drug Safety Monitoring”

16:50-17:05 David Harel, CytoReason: “Data-driven Approach to Discover and Develop Immunotherapy Solutions”

17:05-17:20 Ellen Leinfuss, SVP and Chief Commercial Officer, Certara: “Modeling and Simulations Lead Efficient and Effective Drug Development”

17:20-17:35 Nadav Navon, Chief Operating Officer, Intec Pharma: “The Accordion Pill a Unique Oral Delivery Platform to Enhance Pharmacokinetics and Therapeutic Benefit of Challenging Drugs”

17:35-17:45 Iris Grossman, PhD Chief Scientific Officer, Camp4 Therapeutics: “Closing Remarks”

Wednesday, May 16, 2018

09:30  -  11:30
Hall A

Plenary Session

09:30-09:50 Aharon Aharon, CEO, Israel Innovation Authority

09:50 – 10:50 Corporate Panel: Corporate Investing: Can Strategics Rescue Cash-Starved Start-Ups?
Moderator: David Cassak, Managing Partner, Innovation In Medtech
Michael Martin, PhD, Global Head, Takeda Ventures, Inc.
Zeev Zehavi, Vice President of Venture Investments, Johnson & Johnson Innovation – JJDC, Inc. (JJDC)
Gil Bar-Nahum, PhD, Managing Director, Jefferies International, London, UK
Michal Silverberg, Managing Director, Novartis Venture Fund
Simon Gisby, Managing Director, Deloitte Corporate Finance LLC
David Neustaedter, Vice President, Venture Capital Medtronic
William Shen, Executive Director, Business Development, Bristol-Myers Squibb

10:50-11:30 Bruce R. Rosengard, MD, Vice President, External Innovation, Medical Devices, Johnson and Johnson Medical Devices:  “Innovation: Challenges and Creative Solutions”

11:30  -  12:00

Coffee Break

12:00  -  17:15
Hall A

Nanomedicine and its Role in New Medical Therapeutics

Chair: Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem

Session 1: Nanomedicine: Future Promises

12:00-12:30 Anand Subramony, PhD, Vice President, Novel Product Technologies, MedImmune: “Nanomedicine and its Role in New Medical Therapeutics”

12:30-13:00 Prof. Dina Ben-Yehuda, PhD, Dean, Hadassah-Hebrew University Faculty of Medicine “Targeted Nanoparticles for Improved Hematological Cancers”

Session 2: Presentation of Start-ups

13:00-13:15 Alon Moran, CEO, BioNanoSim Ltd: “Innovative Nano-carriers for Improved Delivery and Drug Performance”

13-15-13:30 Amotz Shemi, PhD, CEO, Silenseed Ltd: “RNA Interference is Progressing Toward Commercialization – the Case of Phase 2 in Pancreatic Cancer”

13:30-13:45 Yoram Ashery, CEO, Nobio Ltd: “Nobio Nanoparticles for Permanent Antimicrobial Protection”

13:45-14:00 Ronen Eavri, PhD, CEO, Barcode Diagnostics: “Barcoded Nanoparticles for Personalized Drug Screening in Cancer Patients”

14:00-15:30 Lunch Break

15:30-15:45 Amir Bahar, PhD, CEO, Nurami Ltd: “Scaffolds of Electrospun Nanofibers for Soft Tissue Repair”

15:45-16:00 Shlomzion Shen, PhD, MBA, CEO, Seevix Material Sciences Ltd: “Seevix Spidersilk “SVXgro”: First Man-Made Spidersilk Produced With Bio- and Nano-Technology”

Session 3: Nanotechnology Up-scaling Challenges: From Bench to the Market

16:00-16:07 Menashe Levy, PhD, CTO, Clexio Biosciences: “Regulatory and CMC Considerations of Nanotechnology Pharma applications”

16:07-16:15 Shimon Amselem, PhD, Chief Scientist, Delivery Technologies, Adama Ltd: “Challenges in the Development and Up-scaling of Liposomes for Diagnostic Imaging”

16:15-16:30 Frederic Lallemand, PhD, Scientist, Santen SAS, “Challenges in the Up-scaling Manufacturing of Cationic Nanoemulsions

16:30-16:45 Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem: “Challenges in the Development and Up-scaling of Drug-loaded Nanoparticles”

Session 4 Closing Lecture

16:45-17:15 Prof. Ronit Satchi-Fainaro, PhD, Head, Cancer Angiogenesis & Nanomedicine Laboratory, Sackler Faculty of Medicine, Tel Aviv University: “Reverting Cancer’s Poor Prognosis using Precision Nanomedicines Based on Molecular Fingerprints of Long-term vs Short-term Survivors“

12:00  -  17:40
Hall B

From Academic Research to Industry

Chair: Gil Granot-Mayer, CEO, Yeda R&D – Technology Transfer, Weizmann Institute of Science

Block 1 – Life Cycle of Technology Transfer – From Initial Disclosure to Success Story

12:00 Gil Granot-Mayer, CEO, YEDA; “Introduction”

12:00-12:35 Panel:  Looking at Both Sides of the Curtain with Technology Transfer – New Technology Transfer Practices, the Convergence of Digital Technology into the Pharma World, Commercializing Platforms, and Better Understanding of what is Driving TTO Policy
Moderator: Mr. Benjamin Soffer, CEO, T3
Tamar Raz, CEO. Hadasit
Sylvie Luria, CEO Sheba
Yaron Daniely, CEO, Yissum
Shlomo Nimrodi, CEO, Ramot
Netta Cohen, CEO, BGN Technologies
Gil Granot-Mayer, CEO, Yeda
Larry Loev, CEO, Ariel Scientific Innovations

12:35-13:00 Showcase of New Start-ups from Academia Part 1 of 3
Moderator: Larry Loev, CEO, Ariel Scientific Innovations
Yitshak Francis, Scientific Advisor, Qrons; Ariel University
Yoram Eshel, CEO, On-Sight; Weizmann Institute of Science
Prof. Fuad Fares, Founder, CanCuRX; Haifa University
Jessica Weiss, CEO, Lydus Medical; Clalit

13:00-13:55 Major Israeli Success Stories in Life Sciences – Fireside Chat with Professors who Championed Academic Innovation into Industry
Moderator: Shay Sela, VP, Business Development of Life Sciences, YEDA
Prof. Michel Revel, MD, PhD, Professor Emeritus, Weizmann Institute of Science and Chief Scientist, Kadimastem Ltd
Prof. Yechezkel “Chezy” Barenholz, Hebrew University of Jerusalem and Founder of Numerous Startups
Prof. Moussa B.H. Youdim, Prof. Emeritus at the Technion, Founder of Numerous Startups, and President & Chief Scientific Officer at Youdim Pharmaceuticals
Prof. Avigidor Scherz, Weizmann Institute of Science and Developed the technology behind Steba BioTech

14:00-15:30 Lunch Break

Block 2 – Creating the Environment for Successful Technology Transfer:

15:30-16:10 Funding and Performing Translational Research – Models in Taking Bench Side Research to Market. (Collaboration with the IIA; Horizon 2020; NIH; Spark (Stanford) programs)
Moderator: Gil Granot-Mayer, CEO, YEDA
Michael Salgaller, Supervisor, Invention Development and Marketing Unit (IDMU), Technology Transfer Center, National Cancer Institute, National Institutes of Health
Pasi Sorvisto, Director, SPARK Finland Program
Leah Klapper, Chief Technology Officer, FutuRx
Prof. Eli Hazum, Head, IDEA program at YEDA
Aviv Zeevi Balasiano, VP, Head of Division – Technology Infrastructure Israel Innovation Authority
Eyal Zimlichman, Deputy Director General, Chief Medical Officer and Chief Innovation Officer at Sheba Medical Center

16:10-16:30 Showcase of New Start-ups from Academia Part 2 of 3
Moderator: Larry Loev, CEO, Ariel Scientific Innovations
Nadav Peles, Co-Founder, Acting CEO, Ta Geza; Sheba
Prof. Noam Shomron, CSO, Variantyx; TAU
Tomer Behor, CEO, RenewSenses; Hebrew University

16:30-17:15 View of the Israeli Life Science Ecosystem – How do we Realize the Potential?
Moderator: Daphna Murvitz, Co-founder & CEO, 8400 Health Network
Zeev Zehavi, Vice President, Venture Investments JnJ
Prof. David Sidransky, MD, General Partner at the Israel Biotech Fund
Einat Zisman, Former CEO of FutuRx
Yuval Ofek, Founder & Chairman at DayTwo
Roni Mamluk, PhD, CEO at Ayala Pharmaceuticals
Itai Kela, Senior Director, Head of Healthcare and Biotechnology, Israel Innovation Authority

17:15-17:50 Showcase of New Start-ups from Academia Part 3 of 3
Moderator: Larry Love, CEO, Ariel Scientific Innovations
Daria Lemann-Blumenthal, CEO, Belkin Laser; Sheba
Hila Goldman Aslan, CEO, DiA Imaging Analysis; Ben Gurion University
Prof. Ayala Pollack, MD, Inventor & Medical Director, OphtimedRx; Clalit
Seth Salpeter, Co-Founder & CTO, CuResponse, Weizmann Institute of Science

17:40 Gil Granot-Mayer, CEO, YEDA; “Closing Remarks”

12:00  -  17:30
Hall C

Cutting Edge Medical Device Technologies: Metabolic, Ophthalmology

Metabolic Chairs: Irit Yaniv, MD, General Partner, Accelmed and Prof. Moshe Phillip, Director of the Institute for Endocrinology and Diabetes, Israel National Center for Childhood Diabetes

Ophthalmology Chair: Barak Azmon, MD, Ophthalmic Entrepreneur

Metabolic Session (Presentations + Q&A by Co-chairs)

12:00-12:17 Yuval Avni, CEO, Beta O2: “Bio Artificial Pancreas”

12:17-12:34 Boaz Behar, CEO, Digma Medical: “Restoring Glycemic Control – Type 2 Diabetes”

12:34-12:51 Eran Atlas, CEO, DreaMed Diabetes: “Ask your Advisor; decision-support technology for patient-specific insulin treatment plans”

12:51-13:08 Dan Hashimshony, PhD, Medical Device Entrepreneur, CEO, Epitomee: “A Self-Administered, Drug-Free Shapeshifting pH Sensitive Super Absorbent Scaffold That Promotes Weight Loss By Balancing Food Consumption”

13:08-13:25 Boaz Brill, CEO, GluSense: “GluSense GlydeTM CGM – a Long-term Implantable Glucose Sensor”

13:25-13:42 Yael Glassman, CEO, Nutrino Health: “How Personalized Nutrition & FoodPrint™ Contributes to Diabetes Care”

13:42-13:59 Christopher R. Shepard, GM/Chief Executive, SmartZyme BioPharma: “Better Continuous Glucose Monitors with a Next-Generation Glucose-Sensing Enzyme”

14:00-15:30 Lunch Break

Ophthalmology Session (Presentation + Q&A by co-chairs & panelists)
Prof. Anat Loewenstein MD, MHA, Head, Ophthalmology Division, Tel Aviv Medical Center
Prof. Ehud Assia, MD, Head, Ophthalmology Division, Meir Medical Center
Elo Kent, Head, Global Innovation , Santen
Barak Azmon, MD, Ophthalmic Entrepreneur

15:30-15:47 Ram Ben-Yehuda, Senior VP Operations, Orcam Technologies: “OrCam – Sophisticated Technology for the Low Vision and Blind”

15:47-16:04 Aryeh Batt, Co-Founder & CEO, Precise Bio: “Bio-manufacturing – Printing the Eye“

16:04-16:21 Nahum Ferera, CEO & Co-Founder, EyeYon Medical“EyeYon Medical – Innovative Solutions for Corneal Healing”

16:21-16:38 Yaakov Milstain, CEO, Nano-Retina: “Artificial Retina”

16:38-16:55 Shahaf Zommer, Project Manager, BeyeOnics-Elbit “Placing the Surgeon in the Center – A Novel 3D Visualization Platform for Eye Surgery Providing Transparent Display, Data Overlay and Guidance”

16:55-17:12 Marc Abitbol, CEO, Visionix, “Visionix: From the Incubator to  a Global Market Leader”

17:12-17:29 Udi Gordon, CEO, CameraEyes: “The Next Generation of Fundus Cameras”


15:30  -  17:00
Hall D

Start-up Competition by Israel Innovation Authority

Alpha Tau Medical

Neurosteer, Prof Nathan Intrator, CEO

NovaSight, Ran Yam, CEO

PixCell Medical, Dr Avishay Bransky

Brainvivo, Assaf Horowitz, CEO

CorNeat Vision, Dr. Gilad Litvin, CMO

TempraMed Israel, Ron Nagar

E-Motion Medical Ltd.

Barimote Ltd,  Lior Fleischer, CEO

SpacePharma, Yair Glick, Director of Microgravity Research

Thursday, May 17, 2018

09:30  -  11:05
Hall A

Plenary Session

09:30-09:45 Winner of Startup Competition
Dr. Ami Appelbaum, Chairman, Israel Innovation Authority

09:45-10:25 Philip Nelson, Director of Engineering at Google Research“Accelerating Bio Discovery with Machine Learning” 

10:25-11:05 Paul R. Biondi, Senior Vice President, Head of Business Development, Bristol-Myers Squibb: “Business Development’s Key Role in Delivering the BMS Strategy”

11:05  -  11:35

Coffee Break

11:35  -  17:25
Hall A

Digital Health, IoT, and Big Data – New Armamentarium in Medicine

Co-Chairs: Anat Naschitz, Managing Director, Orbimed Advisors and Allen Kamer, Managing Partner, OurCrowd Qure

11:35-11:40 Anat Naschitz, Managing Director, Orbimed Advisors

11:40-11:45 Allen Kamer, Managing Partner, OurCrowd Qure

11:45-12:05 Elie Lobel, CEO, Orange Healthcare: “Leveraging Technology & Data For Consumer’s Health Improvement”

12:05-12:40 John D. Halamka, MD, MS, Chief Information Officer, Beth Israel Deaconess System: “Emerging Innovations in Healthcare Information Technology”

12:40-13:15 Peter H.J. van der Goes, Jr., Partner, Head of Healthcare IT and Digital Health Banking at Goldman Sachs: “Healthcare Technology: The Outlook for M&A and Capital Markets Activity”

13:15-13:45 Joshua Milner, MD, Chief, Genetics and Pathogenesis of Allergy Section, National Institute of Health: “Building a System and a Culture of Sharing in the Ever Blurring Line of Clinical and Research Genomics”

13:35-15:05 Lunch Break

15:o5-15:20 Ziv Ofek, Founder and CEO, MDClone: “Liberating the Data: when Big-Data and Innovation Meet”

15:20-15:35 Amir Magner, CEO, CyberMDX: “Strategies for Mitigating Medical Devices Cyber-Security Threats”

15:35-15:50 Ofer Tzadik, COO, TytoCare: “TytoCare: A New Model for Healthcare Delivery”

15:50-16:05 Ran Shaul, Co-Founder, K Health: “Patient Empowerment for Better Health”

16:05-16:20 Ariel Beery, CEO, MobileODT“How MobileODT is Disrupting Women’s Health using AI/ML”

16:20-16:35 Prof. Amir Lerman, MD, Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic: “Patient Derived Care: The Physician’s Perspective”

16:35-16:50 Prof. Shai Shen Orr, Chief Scientist, CytoReason; Faculty of Medicine, Technion: “CytoReason: A Machine Learning Model of the Immune System for Informed Decision Making in Drug Development”

16:50-17:05 Prof. Zohar Yakhini,  School of Computer Science, Herzeliya Inter-Disciplinary Center: “Synthetic DNA – From Regulation to Storage”

17:05-17:25 Philip Nelson, Director of Engineering at Google Research: “Connecting with Industry” 


11:35  -  17:25
Hall B

Personalized Diagnostics and Treatments

Chair: Varda Shalev, MD, MPA, Managing Director, Morris Kahn & Maccabi Research and Innovation Institute at Maccabi Health Care Services

11:35-11:55 Varda Shalev, MD, MPA, Managing Director, Morris Kahn & Maccabi Research and Innovation Institute at Maccabi Health Care Services: “Opening Remarks” & Presentation: “Personalized Medicine and Big Data – Morris Kahn and Maccabi Research and Innovation Institute”

11:55-12:20 Miro Venturi, PhD, Global Head – Diagnostics Biomarkers & Personalized Healthcare, F. Hoffmann-La Roche Ltd: “The Future of Personalized Healthcare: The Interplay of Disease, Information and Technologies”

12:20-12:35 Reuven Duer, PhD, Founder & CEO, Proactive Diagnostics: “Monitoring Chronic Inflammation – Proactive Diagnostics”

12:35-13:00 Randy J. Prebula, Partner, Hogan Lovells, Washington, D.C.:  “FDA Oversight of Personalized and Precision Diagnostics – Increasing Familiarity and Emerging Flexibility”

13:00-13:15 Ran Shaul, Co-Founder, K Health: “What 4K Doctors said about my Symptoms”

113:15-13:30 Joseph Mossel, CEO & Co-Founder, Ibex Medical Analytics Ltd: “Leveraging AI-based Algorithms and Deep Learning for Prostate Cancer Diagnostics”

13:35-15:05 Lunch Break

15:05-15:30 David Fenstermacher, PhD, VP R&D-Bioinformatics, Medimmune

15:30-15:50 Prof. Gideon Rechavi, MD, PhD, Head, Sheba Cancer Research Center

15:50-16:05 Dekel Taliaz, CEO, Taliaz: “Using AI and Real-world Data for the Design of Decision Support Tools for Doctors”

16:05-16:25 Shai Rosenberg, MD, PhD, Neuro-Oncology and Head of Cancer Computational Biology Lab., Hadassah-Hebrew University Medical Center: “Personalized Medicine for Glioma”

16:25-16:40 David Israeli, MD, CEO, Magenta Medical: “First-in-Man Experience with the Transcatheter Renal Venous Decongestion System for the Treatment of Acute Decompensated Heart Failure”

16:40-16:55 Haim Gil-Ad, CEO, NovellusDx: “NovellusDx – Solving the missing piece of Cancer Dx”

16:55-17:10 Lihi Segal, CEO, Day Two: “DayTwo Personalized Nutrition Based on Your Gut Microbiome” 

17:10-17:25 Eldad Shemesh, Cofounder & CEO, Cardiacsense: “Continuous Monitoring Device for Heart Arrhythmia and Hypertension“

11:35  -  17:20
Hall C

Brain Health

Chair: Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers

11:35-11:55 Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers: “Where are we in Research, Treatment and Prevention of Alzheimer Disease and Dementia? – Lessons in Drug Development from the Past Year and the Status of the Current Drugs in Late-phase Development“

11:55-13:05 Panel: “Innovations In-development” to Improve Treatment for Brain Diseases – Challenge the Traditional Drug Development Frameworks
Moderator: Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers
Panelists: :
Mark Carlton, CSO, Cerevance Therapeutics
Michal Schnaider Beeri, PhD, Director, Joseph Sagol Neuroscience Center
Michael C. Irizarry, Vice-President of Early Phase Neurosciences, Eli Lilly
Michael Martin, PhD, Global Head, Takeda Ventures, Inc
Yuval Mor, CEO, Beyond Verbal: “Using Voice and AI to Revolutionize Healthcare by Discovering Vocal Biomarkers”

13:05-13:20 Eyal Baror, CEO, Neuronix Medical

13:20-13:35 Gili Hart, CEO, Mitoconix: “Treating Neurodegeneration by Improving Mitochondria Health”

13:35-15:05 Lunch Break

15:05-16:05 Panel: Getting Closer to Validated Biomarkers
Moderator: Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers
Prof. John Gallacher, Director, Dementia Platform UK, University of Oxford
Michael C. Irizarry, Vice-President of Early Phase Neurosciences, Eli Lilly
Prof. Nir Giladi, MD, Director, Neurology Division, Tel Aviv Sourasky Medical Center

16:05-16:20 Sefi Epel, CEO, BrainMarc: “No Pain No Gain”

16:20-16:35 Adam Shames, Director of Business Development & Strategy, Brainsway: “Deep TMS for the Aging Population”

16:35-16:50 Michal Izrael, VP of R&D ALS & Neurodegenerative Diseases, Kadimastem: “Human Pluripotent Stem Cell Derived Astrocytes for the Treatment of ALS, and Insuling Secreting Islets for the Treatment of Diabetes”

16:50-17:05 Ehab Shakour, CEO, InnoSphere: “InnoSphere Overview”

17:05-17:20 Prof. Jonathan Javitt, Founder & CEO, NeuroRx, Inc: “Suicide is a Druggable Target: Treating Suicidal Depression and PTSD with a Small Molecule NMDA/5-HT2A Dual-targeted Drug Platform”